Delegates will attend this program to learn about the latest advancements in antibody discovery and development, including cutting-edge research on how to identify the correct target for an antibody, and how to streamline the entire development process to get more products out and reduce budget needs.

Attendees will also hear about hot topics such as bispecifics and the latest advancements in antibody drug conjugates (ADCs) and their impact on certain critical therapeutic areas. Key to the conference will be addressing a need for quality antibodies and learning about what leading companies such as Genentech, Bayer, Intrexon and Merck are producing in the way of new antibody treatments.